Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
Headache: The Journal of Head and Face Pain · 2025
DOI: 10.1111/head.14843 ↗Kurz gefasst
Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Samuel K Peasah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for High Value Healthcare, UPMC Health Plan, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Patient Reported Outcome Measures, Calcitonin Gene-Related Peptide Receptor Antagonists, Calcitonin Gene-Related Peptide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Objective
To assess patient reported outcomes of patients with migraine receiving preventative medications, and to compare patient reported outcomes and unplanned care of patients on calcitonin gene–related peptide inhibitors (CGRPi) with those on other preventative medications.
Background
Patient reported outcome measures can be useful in conditions such as migraine with frequent disability. CGRPi are newer migraine preventative medications that can improve patients’ quality of life.
Methods
This was a retrospective cohort analysis of Patient Reported Outcomes Measurement Information System (PROMIS) data combined with administrative claims data from a large regional health plan for adult patients (≥18 years) with migraine who were on preventative medications from January 2019 to March 2022. PROMIS scores of patients on CGRPi were compared to scores of patients who switched from other preventative medications to CGRPi (pre vs. post), between patients adherent to CGRPi versus non‐adherent, and changes in all‐cause/migraine‐related unplanned care (emergency department) use by the CGRPi cohort.
Results
There were 1245 patients on other preventative medications (antiseizure [532/1245 (43%)], antidepressants [316/1245 (25%)], and beta‐blockers [397/1245 (32%)]), 148 who were on CGRPi, and 112 who had switched from other preventative medications to CGRPi. The mean age was 44 years old, 88% were females, 50% were married, and 75% were on commercial insurance. Patients with migraine had higher T ‐scores in pain, fatigue, anxiety, and sleep disturbance than the general population. Patients on CGRPi had a statistically significant reduction in pain T ‐scores (60.4 [standard deviation (SD) 7.4] to 58.4 [SD 8.2], p = 0.003) post initiation of medications, especially those who switched from other preventative medications to CGRPi (61.4 [SD 6.9] to 58.7 [SD 8.3], p < 0.001). The pain T ‐score reduction occurred only among the adherent group. There was a lower proportion of patients with all‐cause unplanned care among patients on CGRPi (43% [64/148] to 32% [47/148], p < 0.001), but the reduction in migraine‐related unplanned care was not statistically significant (9% [14/148] to 6% [9/148], p = 0.197).
Conclusion
Our findings suggest that patients had an improvement in pain reduction scores after initiating CGRPi. PROMIS scores could provide important information about quality‐of‐life improvement for prescribers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for High Value Healthcare, UPMC Health Plan, Pittsburgh, Pennsylvania, USA.
- School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- UPMC Health Plan, Pittsburgh, Pennsylvania, USA.
- Department of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Jennifer Nguyen
Zitieren
APA
Peasah, S. K., Soh, Y. H., Huang, Y., Nguyen, J., Hanmer, J., & Good, C. (2025). Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14843
Vancouver
Peasah SK, Soh YH, Huang Y, Nguyen J, Hanmer J, Good C. Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14843
BibTeX
@article{Peasah2025,
author = {Peasah, Samuel K and Soh, Yu Hyeon and Huang, Yan and Nguyen, Jennifer and Hanmer, Janel and Good, Chester},
title = {Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine},
journal = {Headache: The Journal of Head and Face Pain},
year = {2025},
doi = {10.1111/head.14843}
}
EUVIMED